| Status: Under consideration by AWMSG Scrutiny Panel | |
As an alternative to off-label infliximab for the off-label treatment of Immune Checkpoint Inhibitor (ICI) induced grade 3-4 myocarditis that has not responded to first line immunosuppression with corticosteroids in patients with a left ventricular ejection fraction of less than 40%. |
|
Medicine details |
|
| Medicine name | tocilizumab |
| Formulation | concentrate for solution for infusion |
| Reference number | 6461 |
| Indication | As above |
| Company | various |
| BNF chapter | Malignant disease & immunosuppression |
| Status | Under consideration by AWMSG Scrutiny Panel |
| Scrutiny Panel meeting date | 06/03/2025 |